CoChat
Sign Up
Cited by 352Atrial Fibrillation Management and OutcomesHeart Failure Treatment and ManagementCardiac electrophysiology and arrhythmias

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

Ducharme, Anique, Swedberg, Karl, Pfeffer, Marc A., Cohen-Solal, Alain, Granger, Christopher B., Maggioni, Aldo P., Michelson, Eric L., McMurray, John J.V., Olsson, Lars, Rouleau, Jean L., Young, James B., Olofsson, Bertil, Puu, Margareta, Yusuf, Salim·2006·American Heart Journal
DOI 10.1016/j.ahj.2005.06.036
Open this paper in CoChat — free account

Abstract

Background Atrial fibrillation (AF) is frequent in patients with chronic heart failure (CHF). Experimental and small patient studies have demonstrated that blocking the renin-angiotensin-aldosterone system may prevent AF. In the CHARM program, the effects of the angiotensin receptor blocker candesartan on cardiovascular mortality and morbidity were evaluated in a broad spectrum of patients with symptomatic CHF. CHARM provided the opportunity to prospectively determine the effect of candesartan on the incidence of new AF in this CHF population.Methods 7601 patients with symptomatic CHF and reduced or preserved left ventricular systolic function were randomized to candesartan (target dose 32 mg once daily, mean dose 24 mg) or placebo in the 3 component trials of CHARM. The major outcomes were cardiovascular death or CHF hospitalization and all-cause mortality. The incidence of new AF was a prespecified secondary outcome. Median follow-up was 37.7 months. A conditional logistic regression model for stratified data was used.Results 6379 patients (83.9%) did not have AF on their baseline electrocardiogram. Of these, 392 (6.15%) developed AF during follow-up, 177 (5.55%) in the candesartan group and 215 (6.74%) in the placebo group (odds ratio 0.812, 95% CI 0.662-0.998, P = .048). After adjustment for baseline covariates, the odds ratio was 0.802 (95% CI 0.650-0.990, P = .039). There was no heterogeneity of the effects of candesartan in preventing AF between the 3 component trials (P = .57).Conclusions Treatment with the angiotensin receptor blocker candesartan reduced the incidence of AF in a large, broadly-based, population of patients with symptomatic CHF.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ahj.2005.06.036

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 352

Related

See all

Metadata

Authors
Ducharme, A., Swedberg, K., Pfeffer, M. A., Cohen-Solal, A., Granger, C. B., Maggioni, A. P., Michelson, E. L., McMurray, J. J. V., Olsson, L., Rouleau, J. L., Young, J. B., Olofsson, B., Puu, M., & Yusuf, S.
Affiliations
  • Montreal Heart Institute (CA)
  • Sahlgrenska University Hospital (SE)
  • Brigham and Women's Hospital (US)
  • Duke Medical Center (US)
  • Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
  • AstraZeneca (United States) (US)
  • Western Infirmary (GB)
  • Cleveland Clinic (US)
  • AstraZeneca (Sweden) (SE)
Corresponding author
Ducharme, Anique
ORCID
Venue
American Heart Journal
Publisher
Elsevier BV
Published
2006-07
Volume
152
Issue
1
Pages
86-92
ISSN
0002-8703 (ISSN-L)
DOI
10.1016/j.ahj.2005.06.036
OpenAlex
W2097546089
Cited by
352
References
42
Citations by year
2026: 2 · 2025: 10 · 2024: 12 · 2023: 9 · 2022: 13 · 2021: 10 · 2020: 20 · 2019: 10 · 2018: 11 · 2017: 10 · 2016: 22 · 2015: 14 · 2014: 21 · 2013: 21 · 2012: 13
FWCI
23.46
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • American Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
atrial fibrillation, chronic heart failure, candesartan, angiotensin receptor blockers, renin-angiotensin-aldosterone system blockade, atrial fibrillation prevention, CHARM trial, cardiovascular mortality, heart failure hospitalization
MeSH terms
Aged, Atrial Fibrillation, Benzimidazoles, Biphenyl Compounds, Female, Heart Failure, Humans, Male, Middle Aged, Prospective Studies, Renin-Angiotensin System, Tetrazoles, Comorbidity, Logistic Models, Randomized Controlled Trials as Topic, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review